ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/haematology/myeloproliferative-neoplasms
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Myeloproliferative neoplasms
27
trial(s) found.
NCT07008118
Haem
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms (
INCA035784-101
)
bispecific T-cell engager,CALR-targeting
Myeloproliferative Neoplasm
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06499285
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW) (
2024-516009-22-00--KER-050-D301
)
modified ActRIIA ligand trap protein
placebo
Myelodysplastic syndrome
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT06479135
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (
POIESIS
)
JAK1/JAK2 inhibitor
MDM2 inhibitor
placebo
Myelofibrosis
NSW
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06465953
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (
PyramIDH
Study)
DNA methyltransferase inhibitor
IDH1 R132 inhibitor
antimetabolite
Myelodysplastic syndrome
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06372717
Haem
Phase 1
Recruiting
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and/or in Combination With Azacitidine in Adults With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB) (
AP30CP01
)
DNA methyltransferase inhibitor
antimetabolite
multikinase inhibitor,integrated stress response-targeting
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06351631
Haem
Phase 3
Recruiting
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study (
2023-506996-89-00--3543-017
)
LSD1 inhibitor
Myelofibrosis
Polycythemia vera
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05949684
Haem
Phase 3
Recruiting
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "
ELEMENT-MDS
" Trial
recombinant human ActRIIb fusion protein
Myelodysplastic syndrome
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4217 - Benowa - Pindara Private Hospital
NCT05936359
Haem
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (
2022-502514-86-00--INCA-33989-101
)
JAK1/JAK2 inhibitor
anti-CALR monoclonal antibody
Myeloproliferative Neoplasm
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05636514
Haem
Phase 1
Recruiting
A Phase I Study of Oral Decitabine and Cedazuridine (ASTX727) In Combination With Defactinib (VS-6063) as Therapy of Myelodysplastic Syndromes and Low-blast Acute Myeloid Leukaemia (
CELESTIAL-MDS
)
DNA methyltransferase inhibitor
FAK inhibitor
cytidine deaminase inhibitor
Acute myeloid leukaemia
Chronic myelomonocytic leukaemia
Myelodysplastic syndrome
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
NCT05269771
Paed
No longer available
Treatment Plan for Managed Access Program (MAP) to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera (PV) (
CINC424B2002I
)
JAK1/JAK2 inhibitor
Polycythemia vera
NSW
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
NCT05037760
Haem
Phase 2
Recruiting
A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis (
KER050-MF-301
)
JAK1/JAK2 inhibitor
modified ActRIIA ligand trap protein
Myelofibrosis
NSW
2139 - Concord - Concord Repatriation General Hospital
2485 - Tweed Heads - The Tweed Hospital
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
3066 - Epping - Northern Hospital
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05005299
Haem
Phase 1
Recruiting
The
VICTORY
Study: A Phase I Study of Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation
Bcl2 inhibitor
Leukaemia
Multiple myeloma
Myelodysplastic syndrome
Non-Hodgkin's lymphoma
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
NCT04771130
Haem
Phase 1
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (
2021-003285-12--BGB-11417-103
)
Bcl2 inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04655118
Haem
Phase 2
Recruiting
A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis (
TL-895-201
)
BTK inhibitor
Myelofibrosis
Systemic mastocytosis
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2217 - Kogarah - St George Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT04581512
Haem
Phase 1
Recruiting
A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies (
EP0042-101
)
FLT3/Aurora inhibitor
Acute myeloid leukaemia
Chronic myelomonocytic leukaemia
Myelodysplastic syndrome
WA
6000 - Perth - Royal Perth Hospital
NCT04419649
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (
KER050-MD-201
)
modified ActRIIA ligand trap protein
Myelodysplastic syndrome
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04176198
Haem
Phase 1
Recruiting
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis (
BBI-TP-3654-102
)
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
Momelotinib
Ruxolitinib
cancer therapy
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
Myelofibrosis
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04064060
Haem
Phase 3
Recruiting
A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials (
U1111-1235-8123--ACE-536-LTFU-001
)
recombinant human ActRIIb fusion protein
Myelodysplastic syndrome
Myelofibrosis
NOT Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT03850574
Haem
Phase 1
Recruiting
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) (
TUSCANY
)
Azacitidine
Bcl2 inhibitor
DNA methyltransferase inhibitor
Venetoclax
antimetabolite
cancer therapy
cancer therapy,Bcl2-targeting
cancer therapy,DNA methyltransferase-targeting
cytotoxic chemotherapy
Chronic myelomonocytic leukaemia
Leukaemia
Myelodysplastic syndrome
NSW
2640 - Albury - Border Medical Oncology Research Unit
VIC
3066 - Epping - Northern Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4812 - Townsville - Townsville University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03165734
Haem
Phase 3
Recruiting
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/µL)(
PACIFICA
)
JAK2 inhibitor
Myelofibrosis
Polycythemia vera
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
ACTRN12624001214527
Haem
Phase 1
Recruiting
A Phase 1 open-label trial to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary antitumor activity of LAVA-1266, a CD123-targeting bispecific gamma delta-T cell engager, in patients with CD123 positive R/R AML and intermediate risk, high risk, or extremely high risk MDS
bispecific T-cell engager,CD123-targeting
Acute myeloid leukaemia
Myelodysplastic syndrome
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3121 - Richmond - Epworth Freemasons Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12624000478516
Haem
Phase 1 / Phase 2
Recruiting
Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis (
JBI-802-102
)
LSD1/HDAC6 inhibitor
Essential thrombocythaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
Myeloproliferative Neoplasm
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12622001302741
Haem
Phase 1 / Phase 2
Not yet recruiting
MDS05/D2 - A multicentre phase Ib/II open label randomized platform design study to determine the safety and efficacy of SRA515 and ASTX727 for treatment of intermediate and high risk Myelodysplastic Syndrome (MDS). (
ALLG
)
BRD4 inhibitor
cytidine deaminase inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
ACTRN12622001232729
Radonc
Phase 2
Recruiting
A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation (
The-ANZHIT-2-study
)
Cyclophosphamide
Fludarabine
Mesna
Radiotherapy
Treosulfan
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
sodium mercaptoethanesulfonate
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Chronic myelogenous leukaemia
Myelodysplastic syndrome
Myeloproliferative Neoplasm
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12622000308796
Haem
Phase 1
Recruiting
A phase 1 study to assess the safety of short-course treatment with venetoclax prior to non-myeloablative stem cell transplantation for patients with haematological malignancies. (
VICTORY-study
)
Bcl2 inhibitor
Chronic lymphocytic leukaemia
Leukaemia
Lymphoma
Multiple myeloma
Myelodysplastic syndrome
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
Warning
: preg_match(): Compilation failed: missing closing parenthesis at offset 42 in
/home/topowadl/articanz.org/table.php
on line
431
ACTRN12621000223831
Haem
Phase 2
Recruiting
Precision Medicine for Chronic Myelomonocytic Leukaemia in Adults: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling. (
PREACH-M-(PREACH-M
)
DNA methyltransferase inhibitor
anti-GM-CSF monoclonal antibody
antimetabolite
Chronic myelomonocytic leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT03662126
Haem
Phase 2
Unknown
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment (
BOREAS
)
MDM2 inhibitor
Myelofibrosis
Polycythemia vera
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
3174 - Noble Park - South Eastern Private Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (24)
No longer available (1)
Not yet recruiting (1)
Unknown (1)
Recruitment Country and State
VIC (20)
NSW (17)
SA (14)
WA (13)
QLD (12)
NZ (5)
Phase
Phase 1 (11)
Phase 1 / Phase 2 (2)
Phase 2 (6)
Phase 3 (7)
Trial Type
Haem (25)
Paed (1)
Radonc (1)
Cancer Therapy Class
DNA methyltransferase
30%
JAK1
22%
JAK2
22%
Bcl2
19%
CALR
7%
MDM2
7%
LSD1
7%
cytidine deaminase
7%
IDH1
4%
IDH1 R132
4%
ISR
4%
multikinase
4%
FAK
4%
BTK
4%
AURKA
4%
AURKB
4%
Aurora
4%
FLT3
4%
CD123
4%
HDAC6
4%
BRD4
4%
GM-CSF
4%
Facility
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (13)
3168 - Clayton - Monash Medical Centre (8)
3004 - Melbourne, Southbank - Alfred Health (7)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (7)
3000 - Melbourne - Peter MacCallum Cancer Centre (7)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
3066 - Epping - Northern Hospital (5)
6000 - Perth - Royal Perth Hospital (5)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (4)
3128 - Box Hill - Box Hill Hospital - Eastern Health (3)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (3)
2217 - Kogarah - St George Hospital (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
2139 - Concord - Concord Repatriation General Hospital (3)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
5042 - Bedford Park - Flinders Medical Centre (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (2)
2485 - Tweed Heads - The Tweed Hospital (2)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
3121 - Richmond - Epworth Freemasons Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (2)
2109 - North Ryde - Macquarie University Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
4217 - Benowa - Pindara Private Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
4215 - Southport - Tasman Oncology (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4812 - Townsville - Townsville University Hospital (1)
NA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (1)
3174 - Noble Park - South Eastern Private Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Myeloproliferative neoplasm
Myelodysplastic syndrome
Leukaemia
Myelofibrosis
Acute myeloid leukaemia
Myeloid leukaemia
Myelodysplastic/Myeloproliferative disease
Polycythaemia vera
Chronic myelomonocytic leukaemia
Lymphoma
Multiple myeloma
Non-Hodgkin's lymphoma
Plasma cell disorder
Lymphoid leukaemia
Mast cell disorder
Systemic mastocytosis
Essential thrombocythaemia
Acute lymphoblastic leukaemia
Chronic leukaemia
Chronic myelogenous leukaemia
B-cell malignancy
Chronic lymphocytic leukaemia
Mature B-cell malignancy
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy